Table 2. Drug-induced early apoptosis in EOC cells in 6 treatment groups.
| SKOV3 cells | A2780 cells | |||
|---|---|---|---|---|
| Treatment group | % AnnexinV+ cells | P* | % AnnexinV+ cells | P* |
| Control | 4.0 ± 0.57 | - | 3.5 ± 0.40 | - |
| AO-1(1 μmol/L) | 4.3 ± 0.48 | - | 3.7 ± 0.38 | - |
| AO-1(100 μmol/L) | 5.1 ± 0.34 | - | 3.2 ± 0.44 | - |
| Paclitaxe l (0.01 μmol/L) | 5.8 ± 0.45 | - | 8.5 ± 0.65 | - |
| Paclitaxel/AO-I (1 μmol/L) | 9.9 ± 0.82* | 0.002 | 9.1 ± 0.51 | 0.336 |
| Paclitaxel/AO-I (100 μmol/L) | 13.6 ± 1.76* | 0.001 | 9.8 ± 1.01 | 0.593 |
EOC cells were treated with paclitaxel (0.01 μmol/L), AO-I (1 μmol/L, 100 μmol/L), and with paclitaxel (0.01 μmol/L) plus AO-I (1 μmol/L, 100 μmol/L) for 24 hours. FCM assay for AnnexinV binding as described in Materials and methods. Data represent mean values ± S.D. from three independent experiments.
*P values, compared with paclitaxel group, AO-1 groups and control group. AO-I significantly potentiates paclitaxel-induced early apoptosis of SKOV-3 cells in a concentration-dependent manner.